title: The effects of thiophosphoric acid (Ukrain) on cervical cancer, stage IB bulky.
abstract: This study was carried out to determine the clinical and immune response of a stage IB voluminous uterine cervical cancer to thiophosphoric acid alkaloid derivatives from Chelidoniium majus L. (Ukrain). The drugs were administered 10 mg intramuscularly every other day, for up to 10 injections. The two largest diameters and tumour volumes were measured and laboratory and immunological tests were performed before and after Ukrain administration. The patients were then operated on with type III Piver's radical hysterectomy. Three out of nine eligible cases had partial responses while six cases remained stable. Decreased total B lymphocytes and suppressor T lymphocytes were observed as well as increased total numbers of T lymphocytes and helper T lymphocytes. There was no single case of clinical or haematological toxicity apart from mild nausea. Two patients were treated with adjuvant radiotherapy due to lymphatic involvement and all nine patients were still alive at least six months after follow-up.
authors.affiliation: Department of Obstectrics and Gynaecology, Faculty of Medicine, Khon Kaen University, Thailand.
authors.forename: P
authors.initials: P
authors.lastname: Pengsaa
authors.forename: W
authors.initials: W
authors.lastname: Wongpratoom
authors.forename: V
authors.initials: V
authors.lastname: Vatanasapt
authors.forename: B
authors.initials: B
authors.lastname: Udomthavornsuk
authors.forename: E
authors.initials: E
authors.lastname: Mairieng
authors.forename: V
authors.initials: V
authors.lastname: Tangvorapongchai
authors.forename: M
authors.initials: M
authors.lastname: Pesi
authors.forename: S
authors.initials: S
authors.lastname: Krusan
authors.forename: V
authors.initials: V
authors.lastname: Boonvisoot
authors.forename: J W
authors.initials: JW
authors.lastname: Nowicky
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000276:immunology; D000328:Adult; D000470:Alkaloids / Q000009:adverse effects / Q000627:therapeutic use*; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects / Q000627:therapeutic use*; D001402:B-Lymphocytes / Q000187:drug effects; D001600:Berberine Alkaloids; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000276:immunology / Q000601:surgery; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007044:Hysterectomy; D007273:Injections, Intramuscular; D008875:Middle Aged; D010617:Phenanthridines; D013601:T-Lymphocytes / Q000187:drug effects; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000601:surgery
chemical_list: D000470:Alkaloids; D000972:Antineoplastic Agents, Phytogenic; D001600:Berberine Alkaloids; D010617:Phenanthridines; C060921:ukrain